Patent is expected to provide additional intellectual property protection until 2040
Prevalence estimates indicate that PH-HFpEF affects over 1,500,000 patients in the U.S.
There are currently no FDA approved treatments for PH-HFpEF
Thursday, February 2, 2023
Tenax Allowed Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.